Paul E.Goss等在2013年31卷11期(Journal of Clinical Oncology))发表题为《Exemestane versus anastrozole in postmenopausal women with eady breast cancer:NCICCTGMA.27-a randomized controlled phase Ⅲ trial》的论著,
Supported by The Karoji Memorial Fund of the Hirosaki University Graduate School of Medicine
The role of hormone therapy in the treatment of ovarian cancer is not clear. Data on the efficacy and safety of antiestrogens and aromatase inhibitors in recurrent ovarian cancer have been accumulated through phase Ⅱ...
supported by the grant of Key Program Foundation of Beijing TCMs Administration(2004-IV15),China
Objective: To investigate the effects of anastrozole combined with Shuganjiangu decoction on osteoblast-like cells. Methods: Human osteoblast-like cells MG-63 were cultured and divided into four groups control, an...
Objective: Postmenopausal women with breast cancer are at increased risk of bone loss because of age related estrogen deficiency face which accelerated with the use of aromatase inhibitors (AIs). We aimed to study ...
Hormonal treatment is widely accepted for the adjuvant treatment of breast carcinoma, in order to get a reduction in the synthesis of estrogen or to block estrogen receptors in tumors that are hormone dependent. There...
Objective: To look for additional markers of molecular biology response to anastrozole, a new aromatase inhibitor, on the growth and mRNA expression level of MCF-7 cell. Methods: We investigated the effect of anastrzo...
Objective To evaluate bioavailability and pharmacokinetics of domestic and imported anastrozole tablets.Methods Twenty Chinese healthy male volunteers were enrolled in a randomized crossover study with a single oral ...